ZOETIS INC

Zoetis secures FDA EUA for Simparica TRIO against New World screwworm, boosting its veterinary portfolio and investor confidence.

Zoetis Inc. shares drop amid market sell‑off, yet remain a potentially dividend‑worthy animal‑health leader with strong fundamentals and global reach.

Zoetis slumps as pet‑health demand softens; the company cuts FY 2026 guidance and pivots to high‑margin products, R&D, and cost cuts to protect margins.

Zoetis gains investor buzz as Michael Burry ups stake & major ETFs rank it high, making the animal‑health pharma a defensive play amid market volatility.

Zoetis stock sees sharp downgrade and 35k share sell‑off, with Piper Sandler cutting target by 29%—investors weigh regulatory risks vs. potential value.

Zoetis 2025 earnings: What investors need to know about revenue growth, pipeline milestones, cost‑control and analyst outlooks

Zoetis Inc., a leading animal health company, is preparing to release its Q2 earnings report, with investors closely watching for insights into its market performance and strategic initiatives.

Zoetis Inc. faces a mixed bag of financial fortunes, with steady growth and resilience in the competitive pharmaceutical industry, but also challenges and vulnerabilities that require strategic innovation to maintain its market leadership.

Zoetis Inc. faces market challenges due to slowing growth and intensifying competition, prompting a recent downgrade by financial analysts.